Mind Medicine (MindMed) Inc.

As of June 30th, 2022, our cash and cash equivalents were $105.7 million compared to $133.5 million at December 31st, 2021. Our goal is to continue to be prudent with how we manage our cash and our expenses. And we believe that our cash and cash equivalents will be sufficient to meet our operating requirements beyond our key development milestones in 2023 and into 2024, which is well over 18 months of cash runway based on our current budget. Finally, I wanted to mention that earlier in the month, the Board of Directors approved a ratio of 1 for 15 reverse share split of the company's common shares. The reverse share split is intended to enable us to achieve several important corporate objectives by providing greater flexibility in considering and planning for future potential business needs and to address the NASDAQ minimum price bid requirement. The reverse share split is expected to take effect after the close of business on August 26, 2022, with the trading expected to begin on a split-adjusted basis for the NASDAQ and the NEO exchanges at market open on August 29, 2022. I'll now turn the call back over to Rob, who will provide some closing comments. Rob?

Thank you, Sean.

As we've demonstrated, the second quarter was marked by steady progress across our development pipeline. But equally as important, we made some key decisions on our corporate strategy and focus that I believe will drive increased success and efficiency. We have a highly talented and committed team here at MindMed who have continued to execute this plan. Our near-term priorities are clear. Advancing the Ongoing Clinical Trials of MM120 in GAD and ADHD. Commencing our Phase 1 Clinical Trial for MM402 in Healthy Volunteers in 2023. And through our collaboration with UHB, initiating a Phase 1 Comparative Pharmacokinetics and Pharmacodynamic Trial of RS and Racemic MDMA in Healthy Volunteers in the third quarter of 2022. Finally, I want to note that we are aware of the letter issued earlier today by SCM MM Holdings. Unfortunately, SCM chose not to directly contact us about their views before issuing the letter. That was disappointing because we are always open to feedback from our shareholders. Nevertheless, we would be receptive to engaging in a constructive dialogue with SCM if they are interested. We're still reviewing their letter and do not plan to address it on this call. Therefore, we ask that your questions be limited to our second quarter updates and the progress of the business that we've discussed today. With that, I'd like to thank you all again for being here today and happy to take any questions.